Quizartnib is one of the most effective monotherapies for the treatment of FLT3-ITD AML and in one Phase II study complete remission was seen in approximately half of the patients and was sustained for an average of 11–13 weeks [169,170]. The gene discussed is FLT3; the disease is acute myeloid leukemia.